Vanda Pharmaceuticals Inc.
Symbol: VNDA (NASDAQ)
4.52
▲ (0.78%) 0.035
Company Description:
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Key Stats
- Today's Open: $4.49
- Today's High: $4.6
- Today's Low: $4.47
- Today's Volume: 269.26K
- Yesterday Close: $4.48
- Yesterday High: $4.635
- Yesterday Low: $4.47
- Yesterday Volume: 331.25K
- Last Min Volume: 0
- Last Min High: $4.515
- Last Min Low: $4.515
- Last Min VWAP: $0
Company Profile
- Name: Vanda Pharmaceuticals Inc.
- Website: https://www.vandapharma.com
- Listed Date: 2006-04-12
- Location: WASHINGTON, DC
- Market Status: Active
- CIK Number: 0001347178
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $264.72M
- Round Lot: 100
- Outstanding Shares: 59.09M
- Asset Type: CS
RECENT FILINGS FOR VNDA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-08 | 4 | View |
| 2025-07-31 | 10-Q | View |
| 2025-07-31 | 8-K | View |
| 2025-07-01 | SCHEDULE 13G | View |
| 2025-06-16 | 4 | View |
| 2025-06-13 | 144 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-05 | S-8 | View |
| 2025-06-05 | 8-K | View |
| 2025-05-27 | DEFA14A | View |
| 2025-05-21 | 4 | View |
| 2025-05-19 | 4 | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-07 | 8-K | View |
| 2025-04-25 | ARS | View |
| 2025-04-25 | DEFA14A | View |
Latest News on VNDA